Test Code NONCR Neuro-Oncology Gene Panel, Rearrangements Only, Tumor
Ordering Guidance
Multiple oncology (cancer) gene panels are available. For more information see Hematology, Oncology, and Hereditary Test Selection Guide.
Necessary Information
Pathology report (final or preliminary), at minimum containing the following information, must accompany specimen for testing to be performed:
1. Patient name
2. Block number-must be on all blocks, slides, and paperwork (can be handwritten on the paperwork)
3. Tissue collection date
4. Source of the tissue
Specimen Required
This assay requires at least 10% tumor nuclei.
-Preferred amount of tumor area with sufficient percent tumor nuclei: tissue 144 mm(2)
-Minimum amount of tumor area: tissue 36 mm(2)
-If ordered in conjunction with CMAPT / Chromosomal Microarray, Tumor, Formalin-Fixed Paraffin-Embedded, the preferred amount of tissue is 430 mm(2), the minimum amount is 180 mm(2).
-These amounts are cumulative over up to 15 unstained slides and must have adequate percent tumor nuclei.
-Tissue fixation: 10% neutral buffered formalin, not decalcified
-For this test, at least 6 mm x 6 mm areas on 4 unstained slides is preferred: this is approximately equivalent to 144 mm(2). The minimum acceptable area is 6 mm x 6 mm on 1 unstained slides: approximately equivalent to 36 mm(2). For specimen preparation guidance, see Tissue Requirement for Solid Tumor Next-Generation Sequencing.
Preferred:
Specimen Type: Tissue block
Collection Instructions: Submit a formalin-fixed, paraffin-embedded tissue block with acceptable amount of tumor tissue.
Acceptable:
Specimen Type: Tissue slide
Slides: 1 Hematoxylin and eosin-stained and 15 unstained
Collection Instructions:
Submit the followings slides:
1 Slide stained with hematoxylin and eosin
AND
15 Unstained, nonbaked slides with 5-micron thick sections of the tumor tissue.
Note: The total amount of required tumor nuclei can be obtained by scraping up to 15 slides from the same block.
Additional information: Unused unstained slides will not be returned.
Useful For
Identifying rearrangements that may support a diagnosis or help determine prognosis for patients with central nervous system tumors
Identifying rearrangements within genes known to be associated with response or resistance to specific cancer therapies
This test is not intended for use for hematological malignancies.
Additional Tests
Test ID | Reporting Name | Available Separately | Always Performed |
---|---|---|---|
SLIRV | Slide Review in MG | No, (Bill Only) | Yes |
Testing Algorithm
When this test is ordered, slide review will always be performed at an additional charge.
Special Instructions
Method Name
Targeted Polymerase Chain Reaction (PCR)-Based Next-Generation Sequencing (NGS)
Reporting Name
Neuro-Onc Panel, Fusions OnlySpecimen Type
VariesSpecimen Minimum Volume
See Specimen Required
Specimen Stability Information
Specimen Type | Temperature | Time |
---|---|---|
Varies | Ambient (preferred) | |
Refrigerated |
Reference Values
An interpretive report will be provided.
Day(s) Performed
Monday through Friday
Report Available
12 to 20 daysPerforming Laboratory

Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
81456
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
NONCR | Neuro-Onc Panel, Fusions Only | 73977-1 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
606325 | Result Summary | 50397-9 |
606326 | Result | 82939-0 |
606327 | Interpretation | 69047-9 |
606328 | Additional Information | 48767-8 |
606329 | Method | 85069-3 |
606330 | Disclaimer | 62364-5 |
606331 | Specimen | 31208-2 |
606332 | Source | 31208-2 |
606454 | Tissue ID | 80398-1 |
606333 | Released By | 18771-6 |